logo

For the Inventor, By the Inventor

New York, NY, United States of America

Lloyd Old

USPTO Granted Patents = 13

 

Average Co-Inventor Count = 6.4

ph-index = 4

Forward Citations = 40(Granted Patents)


Location History:

  • NY, NY (US) (2009)
  • New York, NY (US) (1989 - 2013)

Company Filing History:

goldMedal10 out of 525 
 
Ludwig Institute for Cancer Research Limited
 patents
silverMedal4 out of 1,521 
 
Cornell Research Foundation Inc.
 patents
bronzeMedal3 out of 512 
 
Sloan-kettering Institute for Cancer Research
 patents
4. 2 out of 559 
 
Memorial Sloan Kettering Cancer Center
 patents
5. 1 out of 3 
 
Institute of Molecular Biology and Genetics National Academy of Science of Ukraine
 patents
6. 1 out of 832,843 
Other
 patents
where one patent can have more than one assignee

Years Active: 1989-2013

Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents
1. 8603474 - Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy (2013-12-10),
2. 8440807 - A34 and A33-like 3 DNA protein, antibodies thereto and methods of treatment using same (2013-05-14),
3. 8071717 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof (2011-12-06),
4. 7795409 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per SE, and uses thereof (2010-09-14),
5. 7622568 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof (2009-11-24),
6. 7521543 - A34 and A33-like 3 DNA, proteins, antibodies thereto and methods of treatment using same (2009-04-21),
7. 7354992 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof (2008-04-08),
8. 7132507 - Isolated cancer associated antigens NY-MEL 1 and NY-MEL 3, peptides based thereon, and their uses (2006-11-07),
9. 6911529 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof (2005-06-28),
10. 6774226 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof (2004-08-10),
11. 6448073 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof (2002-09-10),
12. 5009995 - Monoclonal antibodies to melanoma cells (1991-04-23),
13. 4806628 - Monoclonal antibodies against melanocytes (1989-02-21),

Title: The Innovative Contributions of Lloyd Old

Introduction

Lloyd Old is a prominent inventor based in New York, NY, known for his significant contributions to cancer therapy through innovative research and development. With a total of 13 patents to his name, he has made remarkable strides in the field of immunotherapy and cancer treatment.

Latest Patents

Among his latest patents is the development of the membrane transporter NaPi2b (SLC34A2) epitope for antibody therapy. This invention focuses on the use of the SLC34A2 epitope peptide, which encompasses amino acids 312-340, as a target for ovarian cancer therapy. The monoclonal antibody MX35 has been identified as a key component in recognizing this epitope. Additionally, Lloyd's work includes the creation of antibodies specifically directed against NaPi2b (SLC34A2) and methods for generating an immune response to treat tumors and cancer. Another notable patent involves A34 and A33-like 3 DNA protein, which describes polynucleotide and polypeptide molecules, along with methods for detecting cancers that express these proteins.

Career Highlights

Lloyd Old has had a distinguished career, working with esteemed organizations such as the Ludwig Institute for Cancer Research Limited and Cornell Research Foundation Inc. His research has significantly advanced the understanding of cancer immunotherapy and has paved the way for new treatment methodologies.

Collaborations

Throughout his career, Lloyd has collaborated with notable professionals in the field, including Dirk Jager and Matthew J. Scanlan. These collaborations have further enhanced the impact of his research and innovations.

Conclusion

Lloyd Old's contributions to cancer therapy through his innovative patents and collaborations have made a lasting impact in the field of medical research. His work continues to inspire advancements in immunotherapy and cancer treatment methodologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…